Ideaya Biosciences Stock Price, News & Analysis

IDEAYA Biosciences (NASDAQ: IDYA) announced the granting of inducement stock options to a new employee. The Compensation Committee approved non-qualified stock options to purchase 31,400 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan.

The stock options were granted at an exercise price of $24.35 per share, matching IDEAYA's closing price on the grant date. The options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, subject to continued employment.

IDEAYA Biosciences (NASDAQ:IDYA) announced that results from their Phase 2 study of neoadjuvant darovasertib in primary uveal melanoma will be presented at ESMO 2025 in Berlin. The study includes data from over 90 patients across plaque brachytherapy and enucleation-eligible cohorts.

The presentation will highlight darovasertib's potential impact on disease management, particularly notable as it has received FDA Breakthrough Therapy Designation for neoadjuvant use in uveal melanoma patients requiring enucleation. The company has also initiated OptimUM-10, a global Phase 3 neoadjuvant registrational trial, in Q3 2025.

IDEAYA Biosciences (Nasdaq: IDYA) has announced its upcoming 10-Year Anniversary R&D Day, scheduled for September 8, 2025, from 8:00 AM to 10:00 AM ET in New York City. The event will be accessible both in-person and virtually.

The R&D Day will feature presentations of multiple clinical data updates across the company's pipeline, along with discussions about future growth drivers and upcoming milestones. The event will include presentations from IDEAYA's senior leadership team and key opinion leaders in precision medicine oncology.

CEO Yujiro S. Hata will outline the company's strategic vision, priority scientific focus areas, and emerging clinical pipeline as IDEAYA positions itself as a global leader in precision medicine oncology.

IDEAYA Biosciences (NASDAQ:IDYA) and Hengrui Pharmaceuticals announced an upcoming oral presentation at the IASLC 2025 World Conference on Lung Cancer featuring clinical data for IDE849 (SHR-4849), their potential first-in-class DLL3-TOP1 antibody drug conjugate (ADC).

The presentation will showcase efficacy and safety data from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing Phase 1 trial in China. Additionally, IDEAYA initiated a U.S. Phase 1 trial of IDE849 in SCLC patients in Q3 2025. The company will also present a poster demonstrating combination mechanism data between TOP1-payload based ADCs and IDE161, their proprietary PARG inhibitor.

IDE849 targets DLL3, which is upregulated in multiple solid tumors including SCLC, neuroendocrine tumors, non-small cell lung cancer, and melanoma. The presentations will take place at the conference in Barcelona, Spain, from September 6-9, 2025.

IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, will participate in the 2025 BTIG Virtual Biotechnology Conference on July 29th, 2025. The company's President and CEO, Yujiro S. Hata, will engage in a fireside chat at 4:40 PM ET, hosted by BTIG's Director of Biotechnology Research Analysis, Justin Zelin.

The event will be accessible via live audio webcast through the company's investor relations website, with replay available for 30 days after the event.

IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, announced the granting of inducement stock options to a new employee. The Compensation Committee approved non-qualified stock options to purchase 95,600 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan.

The stock options were granted at an exercise price of $22.29 per share, matching IDEAYA's closing price on the grant date. The options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, subject to continued employment.

IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, has announced its participation in two major healthcare investor conferences in June 2025. CEO Yujiro S. Hata will participate in fireside chats at the 2025 Jefferies Global Healthcare Conference on June 4th at 8:10 AM ET, hosted by Dr. Maury Raycroft, and at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9th at 10:40 AM ET, hosted by Corinne Johnson. Live audio webcasts will be available on IDEAYA's investor relations website, with replays accessible for 30 days after the events.

IDEAYA Biosciences (NASDAQ: IDYA) has granted non-qualified stock options to nine newly hired employees as part of their employment inducement package. The Compensation Committee approved options to purchase 664,600 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan. The options were priced at $20.05 per share, matching IDEAYA's closing price on the Nasdaq Global Select Market on the grant date. These 10-year options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, contingent on continued employment.

IDEAYA Biosciences (NASDAQ: IDYA) reported Q1 2025 financial results with $1.05 billion in cash reserves, extending runway into 2029. Key highlights include: Over 300 patients enrolled in darovasertib and crizotinib registrational trial for metastatic uveal melanoma (MUM), with median PFS results targeted by YE 2025. The company received FDA Breakthrough Therapy Designation for darovasertib in neoadjuvant UM treatment. Q1 2025 showed a net loss of $72.2 million, with R&D expenses at $70.9 million and G&A expenses at $13.5 million. IDEAYA's pipeline progress includes IDE849 Phase 1 initiation in the U.S., IDE275 presentation at AACR 2025, and plans for three additional IND filings in 2025 (PRMT5, B7H3/PTK7 ADC, and KAT6/7). The company strengthened its leadership team with new CFO Joshua Bleharski and SVP of Technical Operations Shanthakumar Tyavanagimatt.